An interventional study of Risk stratification in Lung Cancer (Diagnosis), sponsored by Vejle Hospital. Recruiting at 2 sites in Denmark. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Vejle Hospital · Not applicable, Interventional, and Other
The study is a prospective, non-randomized feasibility study evaluating blood sample and machine learning-based risk stratification for lung cancer in patients with COPD (chronic obstructive pulmonary disease).
Patients with COPD will be recruited in general practice, where they will have a blood sample drawn. All data will be analyzed by the machine learning model, and patients with increased risk of lung cancer will be referred for a low-dose CT scan of the chest.
The primary objective of the study is to evaluate the feasibility of AI and DNA methylation-based risk stratification for lung cancer in patients with COPD in a primary care setting.
The secondary objectives are to evaluate the safety of the risk stratification approach, the potential effects on quality of life and wellbeing, to gain insight into the patient and physician perspectives, and to estimate the health economic consequences.
Lung cancer causes the highest number of cancer-related deaths. Around 5000 people are diagnosed with lung cancer annually in Denmark, and people with chronic obstructive pulmonary disease (COPD) have a higher risk compared to the general population. Screening with low-dose computed tomography (LDCT) can reduce the mortality from lung cancer, but patient adherence and LDCT capacity represent considerable challenges.
The selection criteria commonly applied to LDCT screening programs center around age and tobacco consumption resulting in a large number of individuals eligible for screening. A more personalized approach could reduce the resources required for a lung cancer screening program. Smoking is the single greatest risk factor for developing lung cancer, but the damaging effect can vary between individuals. The methylation-level of the AHRR gene was found to be related to the risk of developing lung cancer. Artificial intelligence (AI) is another promising approach to risk evaluation, and a machine learning model based on clinical data and standard blood tests developed by Danish researchers can be used to predict the risk of lung cancer.
The present project aims to investigate the feasibility of blood sample and AI-based risk stratification for lung cancer in patients with COPD treated and followed in general practice.
A thousand patients with COPD will be enrolled by general practitioners located in the general Vejle area in the Region of Southern Denmark. Consenting patients will fill out basic clinical data in an online REDCap database, and then they will have the blood sample collected by a healthcare professional at the general practice clinic. The sample will be transported to the laboratory at Lillebaelt Hospital, Vejle, for analysis.
A collaborative group at Lillebaelt Hospital Vejle will perform the risk stratification including analyzing DNA methylation and running the AI algorithm. Patients with a score indicating increased risk of lung cancer will be referred for LDCT.
The project will evaluate both feasibility, safety, economy and the experiences of the participants and health care professionals.
5,422 studies on the registry are indexed under Lung Neoplasms; 1,346 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 60 across 3,656 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Vejle Hospital is the lead sponsor of 95 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Risk stratification for lung cancer using standard blood tests, machine learning and a DNA methylation analysis.
Other: Risk stratification
Patients with COPD will have their risk of lung cancer evaluated using a machine learning model incorporating clinical data and standard blood tests as well as a DNA methylation biomarker. If the risk of lung cancer is above the cut-off, the patient will be referred for a low-dose CT scan of the chest. Currently smoking patients will be referred for a smoking cessation program.
The fraction of patients consenting to participate in the study.
The fraction of patients consenting to participate in the study.
Time frame: 2 years
Number of low-dose CT scans performed
The total number of low-dose CT scans performed in the study
Time frame: 2 years
Number of correctly identified lung cancer cases
The number of correctly identified lung cancer cases when evaluated by the machine learning model, the DNA methylation biomarker, the PLCOm2012 model, and the USPSTF lung cancer screening criteria.
Time frame: Up to 8 years
Number of lung cancer cases
The total number of lung cancer cases identified during the study and during 6 years of subsequent follow-up.
Time frame: Up to 8 years
Stage distribution of lung cancer cases
The number of lung cancer cases identified within each stage from I-IV.
Time frame: Up to 8 years
Number of patients with incidental findings on low-dose CT
The total number of patients with an incidental finding on the low-dose CT scan requiring treatment or further diagnostic procedures.
Time frame: 2 years
Number of patients without malignant disease who undergo invasive diagnostic procedures
The number of patients who undergo invasive diagnostic procedures who do not have a lung cancer diagnosis at one and two years of follow-up.
Time frame: Up to 4 years
Number of adverse events
The number of adverse events in the form of pneumothorax, bleeding, infection and hospital admission.
Time frame: 2 years
Number of patients who initiate smoking cessation
The number and fraction of active smokers initiating and maintaining a smoking cessation program.
Time frame: Up to 4 years
The fraction of participants who adhere to the study protocol
The fraction of participants who have the blood sample drawn, and when applicable, the fraction of referred participants who undergo low-dose CT.
Time frame: 2 years
Differences in World Health Organization Five Well-being Index (WHO-5) score
Differences in World Health Organization Five Well-being Index (WHO-5) score between patients with and without increased risk of lung cancer after 1 month and 12 months. The scale minimum is 0 and the maximum is 100. A higher score indicates a better outcome.
Time frame: Up to 3 years
Differences in Anxiety Symptom Scale 2 (ASS-2) score
Differences in Anxiety Symptom Scale 2 (ASS-2) score between patients with and without increased risk of lung cancer after 1 month and 12 months. The scale minimum is 0 and the maximum is 10. A lower score indicates a better outcome.
Time frame: Up to 3 years
Differences in Major Depression Inventory 2 (MDI-2) score
Differences in Major Depression Inventory 2 (MDI-2) score between patients with and without increased risk of lung cancer after 1 month and 12 months. The scale minimum is 0 and the maximum is 10. A lower score indicates a better outcome.
Time frame: Up to 3 years
Differences in EQ-5D-5L (quality of life) score
Differences in EQ-5D-5L score between patients with and without increased risk of lung cancer after 1 month and 12 months. Each of the five domains in the scale has a minimum of 1 and the maximum of 5. A lower score indicates a better outcome. The visual analog scale has a minimum of 0 and a maximum of 100. A higher score indicates a better outcome.
Time frame: Up to 3 years
Health economic consequences
The estimated health economic consequences of implementing AI and DNA methylation-based risk stratification in a primary healthcare setting including an estimation of the extra workload placed in the primary healthcare sector. A cost-utility analysis will calculate the incremental quality-adjusted life years (QALYs) gained by the program.
Time frame: Up to 8 years
Qualitative analysis of interview data
Selected participants and general practitioner clinics will be invited to participate in interviews. They will inform about their experiences with the study, the intervention, the setting, the logistics and other thoughts, considerations and barriers they might have.
Time frame: 3 years.
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Apr 2028, 23 months after the start.
Of 864 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 68. This study's planned 23 months is below that.
Counting every sponsor, half of 915 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vejle Hospital